Sponsors

Sponsors


November 16 & 17, 2018
Edmonton Clinic Health Academy, University of Alberta
Edmonton, Alberta

 

Registration is Now Open

Accreditation Update

The group learning program has been reviewed by the College of Family Physicians of Canada and is awaiting final certification by the College’s Alberta Chapter.

This is an accredited group learning activity (Section 1) defined in the Royal College of Physicians and Surgeons Continuous Certification Program and approved by the Office of Continuing Medical Education and Professional Development. from the University of Calgary. You can request a maximum of 9.75 hours.

 

SPONSORS

We would like to take the time to thank the sponsors of this conference for their support. These companies include:

And of course, our conference host,  The Sickle Cell Foundation of Alberta

We would also like to acknowledge the funding provided by the President’s Fund of the Canadian Institutes of Health Research and the funding provided by Dr. Robert Turner’s grant for blood disease research.

 

Become a sponsor!

In 2018, at the (Re) Imagining Health Conference, prestigious international researchers will present and be available to meet with members of local medical, dental and pharmacy faculties. Our studies show that there is a great deal of research going on in the field of gene therapy and other drugs for sickle cell disease. CFAS wishes to offer this opportunity to academics, students, medical staff and patients from Canadian universities.

If you would like to sponsor the 2018 Health Conference, please see the sponsorship pamphlet and/or contact us at  Sponsorship Prospectus and/or contact us at  SCFA@buksa.com

 

REGISTRATION IS NOW OPEN

CLICK HERE TO SIGN UP

Top Image: Cydcor Offices via  Flickr
 

Did you know?

The only known cure for Sickle Cell Disease is a stem cell transplant (or bone marrow transplant). Due to the difficulty in finding an identical match and the significant risks involved in this procedure, including life-threatening complications, it is rarely an option for sickle cell patients.